Aggregation formation in the polyglutamine diseases: Protection at a cost?

Molecules and Cells

Volumn 36, Issue 3, 2013, Pages 185-194

  Todd, Tiffany W ^a   Lim, Janghoo ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggregation; Neurodegeneration; Oligomerization; Polyglutamine

Indexed keywords

POLYGLUTAMINE; MUTANT PROTEIN; PEPTIDE;

CELL NUCLEUS INCLUSION BODY; CLINICAL PATHWAY; CYTOTOXICITY; DEGENERATIVE DISEASE; DISEASE CLEARANCE; HUMAN; IN VITRO STUDY; INTERVENTION STUDY; NONHUMAN; POLYGLUTAMINE DISEASE; SHORT SURVEY; TOXICITY; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PROTEIN CONFORMATION; PROTEIN FOLDING; REVIEW; SIGNAL TRANSDUCTION; NEURODEGENERATIVE DISEASES;

ANIMALS; HUMANS; MICE; MUTANT PROTEINS; NEURODEGENERATIVE DISEASES; PEPTIDES; PROTEIN CONFORMATION; PROTEIN FOLDING; SIGNAL TRANSDUCTION;

EID: 84898246321     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.1007/s10059-013-0167-x     Document Type: Short Survey

References (114)

1. Abel, A., Walcott, J., Woods, J., Duda, J., and Merry, D.E. (2001). Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Hum. Mol. Genet. 10, 107-116.
2. Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H., Do, J., Sang, C., Kobayashi, Y., Doyu, M., and Sobue, G. (2001). Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death. Hum. Mol. Genet. 10, 1039-1048.
3. Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Pagoulatos, G., Angelidis, C., Kusakabe, M., Yoshiki, A., Kobayashi, Y., Doyu, M., et al. (2003). Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J. Neurosci. 23, 2203-2211.
4. Adachi, H., Waza, M., Tokui, K., Katsuno, M., Minamiyama, M., Tanaka, F., Doyu, M., and Sobue, G. (2007). CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J. Neurosci. 27, 5115-5126.
5. Al-Ramahi, I., Lam, Y.C., Chen, H.-K., de Gouyon, B., Zhang, M., Perez, A.M., Branco, J., de Haro, M., Patterson, C., Zoghbi, H.Y., et al. (2006). CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J. Biol. Chem. 281, 26714-26724.
6. Arrasate, M., and Finkbeiner, S. (2012). Protein aggregates in Huntington's disease. Exp. Neurol. 238, 1-11.
7. Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R., and Finkbeiner, S. (2004). Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810.
8. Baldo, B., Paganetti, P., Grueninger, S., Marcellin, D., Kaltenbach, L.S., Lo, D.C., Semmelroth, M., Zivanovic, A., Abramowski, D., Smith, D., et al. (2012). TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. Chem. Biol. 19, 264-275.
9. Bates, G. (2003). Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361, 1642-1644.
10. Bauer, P.O., and Nukina, N. (2009). The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem. 110, 1737-1765.
11. Bauer, P.O., Goswami, A., Wong, H.K., Okuno, M., Kurosawa, M., Yamada, M., Miyazaki, H., Matsumoto, G., Kino, Y., Nagai, Y., et al. (2010). Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat. Biotechnol. 28, 256-263.
12. Becher, M.W., Kotzuk, J.A., Sharp, A.H., Davies, S.W., Bates, G.P., Price, D.L., and Ross, C.A. (1998). Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol. Dis. 4, 387-397.
13. Behrends, C., Langer, C.A., Boteva, R., Böttcher, U.M., Stemp, M.J., Schaffar, G., Rao, B.V., Giese, A., Kretzschmar, H., Siegers, K., et al. (2006). Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol. Cell 23, 887-897.
14. Bennett, M.J., Huey-Tubman, K.E., Herr, A.B., West, A.P., Ross, S.A., and Bjorkman, P.J. (2002). A linear lattice model for polyglutamine in CAG-expansion diseases. Proc. Natl. Acad. Sci. USA 99, 11634-11639.
15. Bodner, R.A., Outeiro, T.F., Altmann, S., Maxwell, M.M., Cho, S.H., Hyman, B.T., McLean, P.J., Young, A.B., Housman, D.E., and Kazantsev, A.G. (2006). Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc. Natl. Acad. Sci. USA 103, 4246-4251.
16. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C.M., and Stefani, M. (2002). Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511.
17. Burke, K.A., Godbey, J., and Legleiter, J. (2011). Assessing mutant huntingtin fragment and polyglutamine aggregation by atomic force microscopy. Methods 53, 275-284.
18. Chafekar, S.M., Wisén, S., Thompson, A.D., Echeverria, A., Walter, G.M., Evans, C.G., Makley, L.N., Gestwicki, J.E., and Duennwald, M.L. (2012). Pharmacological tuning of heat shock protein 70 modulates polyglutamine toxicity and aggregation. ACS Chem. Biol. 7, 1556-1564.
19. Chen, S., Berthelier, V., Yang, W., and Wetzel, R. (2001). Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J. Mol. Biol. 311, 173-182.
20. Chen, S., Ferrone, F.A., and Wetzel, R. (2002). Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl. Acad. Sci. USA 99, 11884-11889.
21. Cooper, J.K., Schilling, G., Peters, M.F., Herring, W.J., Sharp, A.H., Kaminsky, Z., Masone, J., Khan, F.A., Delanoy, M., Borchelt, D.R., et al. (1998). Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet. 7, 783-790.
22. Cowin, R.-M., Roscic, A., Bui, N., Graham, D., Paganetti, P., Jankowsky, J.L., Weiss, A., and Paylor, R. (2012). Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse. Behav. Brain Res. 229, 308-319.
23. Cummings, C.J., Mancini, M.A., Antalffy, B., DeFranco, D.B., Orr, H.T., and Zoghbi, H.Y. (1998). Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 19, 148-154.
24. Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L., and Bates, G.P. (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548.
25. Davies, S.W., Beardsall, K., Turmaine, M., DiFiglia, M., Aronin, N., and Bates, G.P. (1998). Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet 351, 131-133.
26. Davies, S.W., Turmaine, M., Cozens, B.A., Raza, A.S., Mahal, A., Mangiarini, L., and Bates, G.P. (1999). From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 354, 981-989.
27. DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P., and Aronin, N. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993.
28. Doi, H., Adachi, H., Katsuno, M., Minamiyama, M., Matsumoto, S., Kondo, N., Miyazaki, Y., Iida, M., Tohnai, G., Qiang, Q., et al. (2013). p62/SQSTM1 differentially removes the toxic mutant androgen receptor via autophagy and inclusion formation in a spinal and bulbar muscular atrophy mouse model. J. Neurosci. 33, 7710-7727.
29. Dragatsis, I., Goldowitz, D., Del Mar, N., Deng, Y.P., Meade, C.A., Liu, L., Sun, Z., Dietrich, P., Yue, J., and Reiner, A. (2009). CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiol. Dis. 33, 315-330.
30. Ehrnhoefer, D.E., Duennwald, M., Markovic, P., Wacker, J.L., Engemann, S., Roark, M., Legleiter, J., Marsh, J.L., Thompson, L.M., Lindquist, S., et al. (2006). Green tea (-)-epigallocatechingallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet. 15, 2743-2751.
31. Gong, B., Lim, M.C.Y., Wanderer, J., Wyttenbach, A., and Morton, A.J. (2008). Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Res. Bull. 75, 146-157.
32. Gusella, J.F., and MacDonald, M.E. (2000). Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci. 1, 109-115.
33. Gutekunst, C.A., Li, S.H., Yi, H., Mulroy, J.S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R.J., Hersch, S.M., and Li, X.J. (1999). Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19, 2522-2534.
34. Hammer, N.D., Wang, X., McGuffie, B.A., and Chapman, M.R. (2008). Amyloids: friend or foe? J. Alzheimers Dis. 13, 407-419.
35. Hands, S.L., and Wyttenbach, A. (2010). Neurotoxic protein oligomerisation associated with polyglutamine diseases. Acta Neuropathol. 120, 419-437.
36. Holmberg, M., Duyckaerts, C., Dürr, A., Cancel, G., Gourfinkel-An, I., Damier, P., Faucheux, B., Trottier, Y., Hirsch, E.C., Agid, Y., et al. (1998). Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum. Mol. Genet. 7, 913-918.
37. Howarth, J.L., Kelly, S., Keasey, M.P., Glover, C.P.J., Lee, Y.-B., Mitrophanous, K., Chapple, J.P., Gallo, J.M., Cheetham, M.E., and Uney, J.B. (2007). Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. Mol. Ther. 15, 1100-1105.
38. Howarth, J.L., Glover, C.P.J., and Uney, J.B. (2009). HSP70 interacting protein prevents the accumulation of inclusions in polyglutamine disease. J. Neurochem. 108, 945-951.
39. Jana, N.R., Dikshit, P., Goswami, A., Kotliarova, S., Murata, S., Tanaka, K., and Nukina, N. (2005). Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem. 280, 11635-11640.
40. Jochum, T., Ritz, M.E., Schuster, C., Funderburk, S.F., Jehle, K., Schmitz, K., Brinkmann, F., Hirtz, M., Moss, D., and Cato, A.C.B. (2012). Toxic and non-toxic aggregates from the SBMA and normal forms of androgen receptor have distinct oligomeric structures. Biochim. Biophys. Acta 1822, 1070-1078.
41. Kar, K., Hoop, C.L., Drombosky, K.W., Baker, M.A., Kodali, R., Arduini, I., van der Wel, P.C.A., Horne, W.S., and Wetzel, R. (2013). β-hairpin-mediated nucleation of polyglutamine amyloid formation. J. Mol. Biol. 425, 1183-1197.
42. Katsuno, M., Sang, C., Adachi, H., Minamiyama, M., Waza, M., Tanaka, F., Doyu, M., and Sobue, G. (2005). Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc. Natl. Acad. Sci. USA 102, 16801-16806.
43. Kim, M., Lee, H.S., LaForet, G., McIntyre, C., Martin, E.J., Chang, P., Kim, T.W., Williams, M., Reddy, P.H., Tagle, D., et al. (1999). Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J. Neurosci. 19, 964-973.
44. Klement, I.A., Skinner, P.J., Kaytor, M.D., Yi, H., Hersch, S.M., Clark, H.B., Zoghbi, H.Y., and Orr, H.T. (1998). Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95, 41-53.
45. Kondo, N., Katsuno, M., Adachi, H., Minamiyama, M., Doi, H., Matsumoto, S., Miyazaki, Y., Iida, M., Tohnai, G., Nakatsuji, H., et al. (2013). Heat shock factor-1 influences pathological lesion distribution of polyglutamine-induced neurodegeneration. Nat. Commun. 4, 1405.
46. Koyano, S., Uchihara, T., Fujigasaki, H., Nakamura, A., Yagishita, S., and Iwabuchi, K. (1999). Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: triple-labeling immunofluorescent study. Neurosci. Lett. 273, 117-120.
47. Kuemmerle, S., Gutekunst, C.A., Klein, A.M., Li, X.J., Li, S.H., Beal, M.F., Hersch, S.M., and Ferrante, R.J. (1999). Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 46, 842-849.
48. Kvam, E., Nannenga, B.L., Wang, M.S., Jia, Z., Sierks, M.R., and Messer, A. (2009). Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS One 4, e5727.
49. Lansbury, P.T., and Lashuel, H.A. (2006). A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443, 774-779.
50. Lee, W.-C.M., Yoshihara, M., and Littleton, J.T. (2004). Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc. Natl. Acad. Sci. USA 101, 3224-3229.
51. Legleiter, J., Lotz, G.P., Miller, J., Ko, J., Ng, C., Williams, G.L., Finkbeiner, S., Patterson, P.H., and Muchowski, P.J. (2009). Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J. Biol. Chem. 284, 21647-21658.
52. Legleiter, J., Mitchell, E., Lotz, G.P., Sapp, E., Ng, C., DiFiglia, M., Thompson, L.M., and Muchowski, P.J. (2010). Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J. Biol. Chem. 285, 14777-14790.
53. Li, S.H., and Li, X.J. (1998). Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. Hum. Mol. Genet. 7, 777-782.
54. Li, M., Miwa, S., Kobayashi, Y., Merry, D.E., Yamamoto, M., Tanaka, F., Doyu, M., Hashizume, Y., Fischbeck, K.H., and Sobue, G. (1998a). Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann. Neurol. 44, 249-254.
55. Li, M., Nakagomi, Y., Kobayashi, Y., Merry, D.E., Tanaka, F., Doyu, M., Mitsuma, T., Hashizume, Y., Fischbeck, K.H., and Sobue, G. (1998b). Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am. J. Pathol. 153, 695-701.
56. Li, H., Li, S.H., Cheng, A.L., Mangiarini, L., Bates, G.P., and Li, X.J. (1999). Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum. Mol. Genet. 8, 1227-1236.
57. Lotz, G.P., Legleiter, J., Aron, R., Mitchell, E.J., Huang, S.-Y., Ng, C., Glabe, C., Thompson, L.M., and Muchowski, P.J. (2010). Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J. Biol. Chem. 285, 38183-38193.
58. Malik, B., Nirmalananthan, N., Gray, A.L., La Spada, A.R., Hanna, M.G., and Greensmith, L. (2013). Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy. Brain 136, 926-943.
59. Martindale, D., Hackam, A., Wieczorek, A., Ellerby, L., Wellington, C., McCutcheon, K., Singaraja, R., Kazemi-Esfarjani, P., Devon, R., Kim, S.U., et al. (1998). Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet. 18, 150-154.
60. Merry, D.E., Kobayashi, Y., Bailey, C.K., Taye, A.A., and Fischbeck, K.H. (1998). Cleavage, aggregation and toxicity of the expanded androgen receptor in spinal and bulbar muscular atrophy. Hum. Mol. Genet. 7, 693-701.
61. Michalik, A., and Van Broeckhoven, C. (2003). Pathogenesis of polyglutamine disorders: aggregation revisited. Hum. Mol. Genet. 12 Spec No 2, R173-R186.
62. Miller, V.M., Nelson, R.F., Gouvion, C.M., Williams, A., Rodriguez-Lebron, E., Harper, S.Q., Davidson, B.L., Rebagliati, M.R., and Paulson, H.L. (2005). CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J. Neurosci. 25, 9152-9161.
63. Miller, J., Arrasate, M., Brooks, E., Libeu, C.P., Legleiter, J., Hatters, D., Curtis, J., Cheung, K., Krishnan, P., Mitra, S., et al. (2011). Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat. Chem. Biol. 7, 925-934.
64. Montie, H.L., and Merry, D.E. (2009). Autophagy and access: understanding the role of androgen receptor subcellular localization in SBMA. Autophagy 5, 1194-1197.
65. Montie, H.L., Cho, M.S., Holder, L., Liu, Y., Tsvetkov, A.S., Finkbeiner, S., and Merry, D.E. (2009). Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 18, 1937-1950.
66. Morton, A.J., Glynn, D., Leavens, W., Zheng, Z., Faull, R.L.M., Skepper, J.N., and Wight, J.M. (2009). Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol. Dis. 33, 331-341.
67. Muchowski, P.J., Schaffar, G., Sittler, A., Wanker, E.E., Hayer-Hartl, M.K., and Hartl, F.U. (2000). Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. USA 97, 7841-7846.
68. Nagai, Y., Inui, T., Popiel, H.A., Fujikake, N., Hasegawa, K., Urade, Y., Goto, Y., Naiki, H., and Toda, T. (2007). A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 14, 332-340.
69. Nakano, M., Ebina, K., and Tanaka, S. (2013). Study of the aggregation mechanism of polyglutamine peptides using replica exchange molecular dynamics simulations. J. Mol. Model. 19, 1627-1639.
70. Nekooki-Machida, Y., Kurosawa, M., Nukina, N., Ito, K., Oda, T., and Tanaka, M. (2009). Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc. Natl. Acad. Sci. USA 106, 9679-9684.
71. Ordway, J.M., Tallaksen-Greene, S., Gutekunst, C.A., Bernstein, E.M., Cearley, J.A., Wiener, H.W., Dure, L.S., Lindsey, R., Hersch, S.M., Jope, R.S., et al. (1997). Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 91, 753-763.
72. Orr, H.T., and Zoghbi, H.Y. (2007). Trinucleotide repeat disorders. Ann. Rev. Neurosci. 30, 575-621.
73. Palazzolo, I., Nedelsky, N.B., Askew, C.E., Harmison, G.G., Kasantsev, A.G., Taylor, J.P., Fischbeck, K.H., and Pennuto, M. (2010). B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy. J. Neurosci. Res. 88, 2207-2216.
74. Paulson, H.L., Perez, M.K., Trottier, Y., Trojanowski, J.Q., Subramony, S.H., Das, S.S., Vig, P., Mandel, J.L., Fischbeck, K.H., and Pittman, R.N. (1997). Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19, 333-344.
75. Perutz, M. (1994). Polar zippers: their role in human disease. Protein Sci. 3, 1629-1637.
76. Perutz, M.F. (1995). Glutamine repeats as polar zippers: their role in inherited neurodegenerative disease. Mol. Med. 1, 718-721.
77. Perutz, M.F., Johnson, T., Suzuki, M., and Finch, J.T. (1994). Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 91, 5355-5358.
78. Poirier, M.A., Li, H., Macosko, J., Cai, S., Amzel, M., and Ross, C.A. (2002). Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277, 41032-41037.
79. Popiel, H.A., Takeuchi, T., Burke, J.R., Strittmatter, W.J., Toda, T., Wada, K., and Nagai, Y. (2013). Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases. Neurotherapeutics [Epub ahead of print]
80. Ravikumar, B., Vacher, C., Berger, Z., Davies, J.E., Luo, S., Oroz, L.G., Scaravilli, F., Easton, D.F., Duden, R., O'Kane, C.J., et al. (2004). Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36, 585-595.
81. Reiner, A., Del Mar, N., Deng, Y.-P., Meade, C.A., Sun, Z., and Goldowitz, D. (2007). R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice. J. Comp. Neurol. 505, 603-629.
82. Romero, E., Cha, G.-H., Verstreken, P., Ly, C.V., Hughes, R.E., Bellen, H.J., and Botas, J. (2008). Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 57, 27-40.
83. Ross, C.A. (1997). Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 19, 1147-1150.
84. Ross, C.A., and Poirier, M.A. (2005). Opinion: What is the role of protein aggregation in neurodegeneration? Nat. Rev. Mol. Cell Biol. 6, 891-898.
85. Rusmini, P., Simonini, F., Crippa, V., Bolzoni, E., Onesto, E., Cagnin, M., Sau, D., Ferri, N., and Poletti, A. (2011). 17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy. Neurobiol. Dis. 41, 83-95.
86. Sapp, E., Penney, J., Young, A., Aronin, N., Vonsattel, J.P., and DiFiglia, M. (1999). Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J. Neuropathol. Exp. Neurol. 58, 165-173.
87. Sathasivam, K., Lane, A., Legleiter, J., Warley, A., Woodman, B., Finkbeiner, S., Paganetti, P., Muchowski, P.J., Wilson, S., and Bates, G.P. (2010). Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Hum. Mol. Genet. 19, 65-78.
88. Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M.E. (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66.
89. Sánchez, I., Mahlke, C., and Yuan, J. (2003). Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421, 373-379.
90. Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G.P., Davies, S.W., Lehrach, H., and Wanker, E.E. (1997). Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-558.
91. Shao, J., and Diamond, M.I. (2007). Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 16 Spec No. 2, R115-R123.
92. Simeoni, S., Mancini, M.A., Stenoien, D.L., Marcelli, M., Weigel, N.L., Zanisi, M., Martini, L., and Poletti, A. (2000). Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract. Hum. Mol. Genet. 9, 133-144.
93. Skibinski, G.A., and Boyd, L. (2012). Ubiquitination is involved in secondary growth, not initial formation of polyglutamine protein aggregates in C. elegans. BMC Cell Biol. 13, 10.
94. Skinner, P.J., Koshy, B.T., Cummings, C.J., Klement, I.A., Helin, K., Servadio, A., Zoghbi, H.Y., and Orr, H.T. (1997). Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 389, 971-974.
95. Sontag, E.M., Lotz, G.P., Agrawal, N., Tran, A., Aron, R., Yang, G., Necula, M., Lau, A., Finkbeiner, S., Glabe, C., et al. (2012). Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J. Neurosci. 32, 11109-11119.
96. Stott, K., Blackburn, J.M., Butler, P.J., and Perutz, M. (1995). Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 92, 6509-6513.
97. Takahashi, T., Kikuchi, S., Katada, S., Nagai, Y., Nishizawa, M., and Onodera, O. (2008). Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum. Mol. Genet. 17, 345-356.
98. Takahashi, T., Katada, S., and Onodera, O. (2010). Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going? J. Mol. Cell Biol. 2, 180-191.
99. Tanaka, M., Machida, Y., Niu, S., Ikeda, T., Jana, N.R., Doi, H., Kurosawa, M., Nekooki, M., and Nukina, N. (2004). Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10, 148-154.
100. Taylor, J.P., Tanaka, F., Robitschek, J., Sandoval, C.M., Taye, A., Markovic-Plese, S., and Fischbeck, K.H. (2003). Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum. Mol. Genet. 12, 749-757.
101. Tokui, K., Adachi, H., Waza, M., Katsuno, M., Minamiyama, M., Doi, H., Tanaka, K., Hamazaki, J., Murata, S., Tanaka, F., et al. (2009). 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum. Mol. Genet. 18, 898-910.
102. Trottier, Y., Lutz, Y., Stevanin, G., Imbert, G., Devys, D., Cancel, G., Saudou, F., Weber, C., David, G., and Tora, L. (1995). Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378, 403-406.
103. Wacker, J.L., Huang, S.-Y., Steele, A.D., Aron, R., Lotz, G.P., Nguyen, Q., Giorgini, F., Roberson, E.D., Lindquist, S., Masliah, E., et al. (2009). Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease. J. Neurosci. 29, 9104-9114.
104. Wang, A.M., Morishima, Y., Clapp, K.M., Peng, H.-M., Pratt, W.B., Gestwicki, J.E., Osawa, Y., and Lieberman, A.P. (2010). Inhibition of hsp70 by methylene blue affects signaling protein function and ubiquitination and modulates polyglutamine protein degradation. J. Biol. Chem. 285, 15714-15723.
105. Watson, L.M., Scholefield, J., Greenberg, L.J., and Wood, M.J.A. (2012). Polyglutamine disease: from pathogenesis to therapy. S. Afr. Med. J. 102, 481-484.
106. Waza, M., Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Tanaka, F., Inukai, A., Doyu, M., and Sobue, G. (2005). 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11, 1088-1095.
107. Weiss, A., Klein, C., Woodman, B., Sathasivam, K., Bibel, M., Régulier, E., Bates, G.P., and Paganetti, P. (2008). Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J. Neurochem. 104, 846-858.
108. Wetzel, R. (2012). Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. J. Mol. Biol. 421, 466-490.
109. Williams, A., Jahreiss, L., Sarkar, S., Saiki, S., Menzies, F.M., Ravikumar, B., and Rubinsztein, D.C. (2006). Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr. Top Dev. Biol. 76, 89-101.
110. Williams, A.J., Knutson, T.M., Colomer Gould, V.F., and Paulson, H.L. (2009). In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol. Dis. 33, 342-353.
111. Wood, N.I., Pallier, P.N., Wanderer, J., and Morton, A.J. (2007). Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice. Neurobiol. Dis. 25, 342-353.
112. Yang, W., Dunlap, J.R., Andrews, R.B., and Wetzel, R. (2002). Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11, 2905-2917.
113. Yu, Z., Wang, A.M., Adachi, H., Katsuno, M., Sobue, G., Yue, Z., Robins, D.M., and Lieberman, A.P. (2011). Macroautophagy is regulated by the UPR-mediator CHOP and accentuates the phenotype of SBMA mice. PLoS Genet. 7, e1002321.
114. Zhou, H., Li, S.H., and Li, X.J. (2001). Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation. J. Biol. Chem. 276, 48417-48424.